Item 5.07. Submission of Matters to a Vote of Security Holders.

IVERIC bio, Inc. ("IVERIC") held its 2022 annual meeting of stockholders on May 12, 2022. The following is a summary of the matters voted on at that meeting.

(a) IVERIC's stockholders elected Dr. Adrienne Graves and Ms. Christine Miller as Class III directors to serve until the 2025 annual meeting of stockholders, each such director to hold office until her successor has been duly elected and qualified. The results of the stockholders' vote for the election of such Class III directors were as follows:



                                                          Broker
                           For           Withheld       Non-Votes
Adrienne Graves           84,393,059      8,395,468      11,268,075
Christine Miller          92,685,329        103,198      11,268,075

(b) IVERIC's stockholders approved a non-binding, advisory proposal on the compensation of IVERIC's named executive officers, as described in the definitive proxy statement for the 2022 annual meeting of stockholders. The results of the stockholders' vote for such matter were as follows:



                                                   Broker
     For            Against        Abstain       Non-Votes
    91,162,825      1,602,973         22,729      11,268,075

(c) IVERIC's stockholders recommended, in a non-binding, advisory vote, that future advisory votes on the compensation of the Company's named executive officers be held with a frequency of every one year. The results of the stockholders' vote with respect to such matter were as follows:



                                                                Broker
   1 Year         2 Years        3 Years        Abstain       Non-Votes
  91,544,190         31,751      1,175,710         36,876      11,268,075

Consistent with these results, IVERIC's Board of Directors determined that future advisory votes on named executive officer compensation will be held every year until the next required advisory vote on the frequency of shareholder votes on executive compensation.

(d) IVERIC's stockholders ratified the selection of Ernst & Young LLP as IVERIC's independent registered public accounting firm for the current fiscal year. The results of the stockholders' vote for such matter were as follows:


                                                  Broker
     For            Against        Abstain       Non-Votes
   103,982,814         55,418         18,370              0


Item 8.01 Other Events

On May 12, 2022, IVERIC's Board of Directors (the "Board") appointed Ms. Christine Miller, as Chair, Dr. Mark Blumenkranz, as a member, and Mr. Axel Bolte, as a member of its newly formed Business Development and Strategy Committee (the "Committee"). In accordance with IVERIC's Non-Employee Director Compensation Policy (the "Policy") the Board has provided that Ms. Miller is eligible to receive annual cash compensation in the amount of $10,000 for her service as Chair of the Committee and Dr. Mark Blumenkranz and Mr. Axel Bolte are each eligible to receive annual cash compensation in the amount of $5,000 for their service as members of the Committee.


                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses